Matthew B. Klein
CHIEF EXECUTIVE OFFICER, Director · PTC THERAPEUTICS, INC.
- 2025
- Aug 6, 2026
- 14
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Matthew B. Klein files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Neil Gregory Almstead - $16.35M in PTCT purchases and sales in the last 12 months
- Michael Schmertzler - $6.47M in PTCT purchases and sales in the last 12 months
- Mark Elliott Boulding - $4.08M in PTCT purchases and sales in the last 12 months
- Eric Pauwels - $2.61M in PTCT purchases and sales in the last 12 months
- Emma Reeve - $2.49M in PTCT purchases and sales in the last 12 months
- Allan Steven Jacobson - $2.13M in PTCT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Matthew B. Klein?
Matthew B. Klein is a corporate insider, tracked as CHIEF EXECUTIVE OFFICER, Director of PTC THERAPEUTICS, INC. (PTCT). InsiderAlpha holds 14 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Matthew B. Klein submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Matthew B. Klein been buying or selling stock?
Recorded transactions: 0 open-market purchases and 15 open-market sales ($4.48M) across all tracked filings.
